- Home
- ACON vs QLGN Comparison
ACON vs QLGN Comparison
Compare ACON & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- QLGN
- Stock Information
- Founded
- ACON 2008
- QLGN 1996
- Country
- ACON United States
- QLGN United States
- Employees
- ACON N/A
- QLGN N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- QLGN Health Care
- Exchange
- ACON Nasdaq
- QLGN Nasdaq
- Market Cap
- ACON 4.5M
- QLGN 4.7M
- IPO Year
- ACON 2022
- QLGN N/A
- Fundamental
- Price
- ACON $7.47
- QLGN $2.80
- Analyst Decision
- ACON Buy
- QLGN
- Analyst Count
- ACON 2
- QLGN 0
- Target Price
- ACON $481.00
- QLGN N/A
- AVG Volume (30 Days)
- ACON 13.2K
- QLGN 2.5M
- Earning Date
- ACON 08-13-2025
- QLGN 07-21-2025
- Dividend Yield
- ACON N/A
- QLGN N/A
- EPS Growth
- ACON N/A
- QLGN N/A
- EPS
- ACON N/A
- QLGN N/A
- Revenue
- ACON $54,601.00
- QLGN N/A
- Revenue This Year
- ACON $145.39
- QLGN N/A
- Revenue Next Year
- ACON $145.45
- QLGN N/A
- P/E Ratio
- ACON N/A
- QLGN N/A
- Revenue Growth
- ACON N/A
- QLGN N/A
- 52 Week Low
- ACON $6.20
- QLGN $2.74
- 52 Week High
- ACON $3,499.51
- QLGN $13.50
- Technical
- Relative Strength Index (RSI)
- ACON 49.34
- QLGN 35.34
- Support Level
- ACON $7.12
- QLGN $2.77
- Resistance Level
- ACON $7.60
- QLGN $3.29
- Average True Range (ATR)
- ACON 0.35
- QLGN 0.53
- MACD
- ACON 0.04
- QLGN -0.06
- Stochastic Oscillator
- ACON 55.72
- QLGN 1.65
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.